Best GLP-1 With Least Side Effects: 2026 FDA-Label Ranking
You're scared of feeling sick. That's the real reason you're here. You don't want to pay $300 a month to throw up for two weeks and quit. Here's the honest answer, up front.
Key findings — based on current FDA labels
- No GLP-1 is side-effect-free. The gap between them is real, but trial results are population averages, not a guarantee about your response.
- Best balance for weight-loss-first adults (weekly injection): Zepbound (tirzepatide). Labeled adverse-reaction discontinuation runs 4.8–6.7% by dose in pooled weight-loss trials.
- Best for needle-avoiders: Wegovy pill (oral semaglutide 25 mg) or Foundayo (orforglipron). Both FDA-approved daily pills with different rules and trade-offs shown below.
- Highest labeled nausea at the full weight-loss dose: Wegovy injection (semaglutide 2.4 mg). 44% in the STEP-1 trial.
- A controllable tolerability factor: clinician-guided, label-based dose escalation. A small 2025 T2D semaglutide pilot found fewer GI events with a flexible schedule, but it does not establish a universal dosing plan.
Editorial conclusions based on FDA prescribing information cited below. Not medical advice. Talk to a licensed clinician before starting or switching any medication.
Worried about side effects?
See FDA-approved options with ongoing provider support
Ro connects eligible members with licensed providers, messaging, and support for side-effect questions and dose adjustments. It offers FDA-approved injection and pill options, with insurance and cash-pay paths depending on the medication.
Sponsored. Prescription treatment requires clinician approval. Membership and medication costs are separate.
Not ready to choose?
Our free 60-second GLP-1 fit quiz uses your route preference and concerns to help you prepare for a clinician conversation.
Find My GLP-1 Path →This page is not for everyone.
Don't use it to self-pick a medication if you're pregnant or trying to be, have a personal or family history of medullary thyroid cancer or MEN 2, have had pancreatitis or gallbladder disease, take insulin or sulfonylureas, or are dealing with severe vomiting, dehydration, or trouble keeping food down. Talk to a licensed clinician. See our GLP-1 contraindications guide.
“Best for Me” — Start With Your Top Concern
If you only read one section, read this one. Match your top concern to your starting path.
| If your top concern is… | Start with | Why |
|---|---|---|
| Best weight loss with the lowest quit rate | Zepbound (tirzepatide) | 20.2% average weight loss vs 13.7% on Wegovy 2.4 mg in SURMOUNT-5 — with lower GI-event discontinuation (2.7% vs 5.6%). |
| I hate needles | Wegovy pill or Foundayo | Both are FDA-approved daily pills. No injections. Stomach side effects still apply. |
| Semaglutide already made me sick | The 60-second quiz, then a clinician | Don’t self-switch. Document what happened first; the right next step often isn’t the next drug. |
| FDA-approved treatment with provider support | Ro | Ro offers access to licensed providers, ongoing messaging, and FDA-approved options; medication eligibility requires clinician review. |
| Paying cash or coverage does not fit | Ro cash-pay options | Ro also offers FDA-approved cash-pay GLP-1 options, with medication pricing separate from the membership. |
See FDA-approved GLP-1 options through Ro →
Ro connects eligible members with licensed providers, ongoing messaging, and FDA-approved injection or pill options. Membership and medication costs are separate.
What Is the Best GLP-1 With Least Side Effects?
There is no GLP-1 with zero side effects. Every drug in this class causes nausea, vomiting, diarrhea, or constipation in a meaningful share of users. What changes is the rate, the route (pill or shot), the dose, and how fast you raise it.
The useful answer has two parts. FDA-label and head-to-head data show differences between medicines, while dose escalation and clinical support can affect how an individual tolerates treatment. So when readers ask for the best GLP-1 with least side effects, the most useful answer has two parts:
At a drug level
The FDA labels show real differences in reported side-effect rates and in how often people quit. Zepbound generally tracks lower than Wegovy 2.4 mg at weight-loss doses. Foundayo sits in the middle. Saxenda (older daily injection) is on the higher end.
At a starting-plan level
Follow the medication's labeled dose-escalation schedule. If a dose is not tolerated, ask the prescriber before escalating; they may delay escalation, reconsider the dose, or change the treatment plan.
Zepbound is usually the strongest first conversation for weight-loss-first adults who qualify and accept weekly injections. Wegovy pill or Foundayo are the right comparison if needles are the dealbreaker. Regardless of the medicine, follow its label and keep the prescriber involved when side effects affect dosing.
How Do FDA-Label Side Effects Compare Across Weight-Loss GLP-1s?
How to read this table
Pay attention to both the nausea rate (how many people felt sick) and the discontinuation rate (how many quit because of side effects). A drug with high nausea but low discontinuation means most people pushed through. A drug with the opposite means symptoms were severe enough to make people stop.
The FDA warns that adverse-event rates from separate clinical trials can't be directly compared as if all trials were identical — populations, doses, and study lengths differ. Use this as a decision aid, not a ranking.
| Drug | Active ingredient | Route | Nausea | Vomiting | Diarrhea | Constipation | Discontinuation (AE) | Avg weight loss |
|---|---|---|---|---|---|---|---|---|
| Zepbound (incl. KwikPen)lowest discont. | Tirzepatide (dual GLP-1/GIP) | Weekly injection | 25–29% | 8–13% | 19–23% | 11–17% | 4.8–6.7% by dose | 15.0–20.9% at 72 wk |
| Wegovy injection 2.4 mg | Semaglutide 2.4 mg | Weekly injection | 44% | 24% | 30% | 24% | 6.8% | 14.9% at 68 wk |
| Wegovy HD 7.2 mg | Semaglutide 7.2 mg | Weekly injection | 39% | 22% | — | 20% | 5% | Additional reduction beyond 2.4 mg |
| Wegovy pill | Oral semaglutide 25 mg | Daily pill | Similar to injection (per label) | Similar | Similar | Similar | 6.9% (3.4% GI-specific) | 13.6% at 64 wk |
| Foundayo | Orforglipron (non-peptide oral) | Daily pill | 26–35% by dose | 13–24% | 21–25% | 20–27% | 6–10% by dose | 7.4–11.1% at 72 wk |
| Saxenda | Liraglutide 3.0 mg | Daily injection | 39.3% | 15.7% | 20.9% | 19.4% | ~10% | 7.4% at 56 wk |
Sources: Zepbound USPI (DailyMed), Wegovy USPI (DailyMed, 2026 version including 7.2 mg), Foundayo USPI (Eli Lilly, April 2026 FDA approval), Saxenda USPI (DailyMed). Fact-checked .
See FDA-approved GLP-1 options through Ro →
Ro connects eligible members with licensed providers, ongoing messaging, and FDA-approved injection or pill options. Membership and medication costs are separate.
Which GLP-1 Causes the Least Nausea, Vomiting, Diarrhea, or Constipation?
The “lowest side effect” answer changes depending on which side effect you mean.
| If you most want to avoid… | Lowest labeled rate (FDA-approved weight-loss GLP-1s) | Caveat |
|---|---|---|
| Nausea | Zepbound at lower dose range (~25%) and Foundayo 5.5 mg (26%) | Climbs with dose for both |
| Vomiting | Zepbound at the lower end of its dose range (~8%) | Wegovy 2.4 mg ran 24% |
| Diarrhea | Saxenda (20.9%) and Foundayo lower doses (~21%) | Zepbound runs 19–23%; semaglutide-class drugs vary |
| Constipation | Zepbound at lower dose range (~11%) and Wegovy 7.2 mg (20%) | Wegovy 2.4 mg ran 24% |
| Quitting because of side effects | Zepbound 5 mg (4.8%) and Wegovy 7.2 mg (5%) | The most honest tolerability signal |
| Needle-related anything | Wegovy pill or Foundayo | Both FDA-approved daily pills; GI side effects still apply |
What If I Want the Lowest GI Risk and Have Type 2 Diabetes?
This page is built for weight-loss-first readers.
If your priority is type 2 diabetes control, the answer shifts because A1C reduction, cardiovascular and kidney indications, hypoglycemia risk with other diabetes drugs, and insurance coverage all matter — and the dose tier you'd typically use is lower.
A 2025 Bayesian network meta-analysis of 48 randomized trials and 27,729 patients with type 2 diabetes ranked dulaglutide (Trulicity) and lixisenatide lower for nausea, vomiting, and overall GI risk than several other GLP-1 options. Tirzepatide ranked highest for nausea and diarrhea in that diabetes-dose analysis — a different population at different doses than the SURMOUNT-5 head-to-head.
See the diabetes-specific GLP-1 guide →Does Slow Titration Reduce GLP-1 Side Effects?
A small 2025 randomized, open-label semaglutide pilot in 104 adults with type 2 diabetes compared a flexible 16-week schedule with an 8-week label-based schedule. It is useful supporting evidence, not a universal dosing recommendation.
| Standard titration | Flexible / slower titration | |
|---|---|---|
| Nausea rate | 64.2% | 45.1% |
| Average days of nausea | 6.3 days | 2.88 days |
| Withdrawal due to GI events | 19% | 2% |
What “slow titration” actually means
Each medication has its own labeled dose-escalation schedule. Follow that schedule unless your prescriber recommends a change. If a dose is not tolerated, ask before escalating; depending on the medication and situation, the clinician may delay escalation, reconsider the dose, or change the treatment plan.
The pilot found fewer GI events with its flexible schedule, but its sample, population, and protocol were specific. Do not use its intermediate steps or timing as a self-directed plan.
— Script to use with your prescriber
Controllable tolerability levers
| Lever | What you control | What the clinician controls |
|---|---|---|
| Titration speed | Following the labeled schedule and reporting intolerance | Deciding whether to delay escalation or change the plan |
| Constipation plan | Asking before you start | Recommending what’s safe with your other meds |
| Food timing and size | Smaller meals; avoiding heavy meals during dose changes | — |
| Hydration | Showing up to appointments hydrated | Setting a fluid target safe for your kidney/heart history |
| Route preference | Pill vs injection | Whether the route fits your medical picture |
| Prior GLP-1 reaction documentation | Bringing notes | Reading them and adjusting the plan |
| After-hours contact path | Asking who to call | Providing it |
Is Zepbound Easier to Tolerate Than Wegovy?
SURMOUNT-5 was the first direct head-to-head trial of Zepbound (tirzepatide) vs Wegovy (semaglutide) for weight loss. Lilly funded the study. But the numbers were published in The New England Journal of Medicine in 2025, peer-reviewed, and the size of the gap is hard to dismiss.
| Zepbound (tirzepatide) | Wegovy (semaglutide 2.4 mg) | |
|---|---|---|
| Average weight loss at 72 weeks | 20.2% | 13.7% |
| GI-event discontinuation | 2.7% | 5.6% |
| Most reported GI patterns | Diarrhea, looser stools | Nausea, constipation |
Reconciling the FDA labels with the head-to-head trial
| Source | What it says about tolerability | What it actually means for you |
|---|---|---|
| FDA labels (separate trials, can’t be directly compared) | Wegovy 2.4 mg has higher labeled nausea (44%) than Zepbound (25–29%) | Real signal that Wegovy 2.4 mg is harder on the average user, but trials weren’t designed for direct comparison |
| SURMOUNT-5 (head-to-head, peer-reviewed) | Zepbound users were less likely to quit due to GI side effects (2.7% vs 5.6%) | The strongest tolerability signal between these two drugs at weight-loss doses |
| Diabetes-population network meta-analyses | Tirzepatide can rank higher for GI risk at T2D doses | Doesn’t apply to weight-loss-dose decisions |
Bottom line
If you're choosing between these two and side effects are your main worry, the head-to-head trial favors Zepbound. If you have established cardiovascular disease or your insurance covers Wegovy at a low copay, the answer changes — Wegovy has the larger heart-outcomes data set (the SELECT trial).
See FDA-approved GLP-1 options through Ro →
Ro connects eligible members with licensed providers, ongoing messaging, and FDA-approved injection or pill options. Membership and medication costs are separate.
Are Oral GLP-1 Pills Easier on Side Effects Than Injections?
If injections are the dealbreaker, you have two FDA-approved daily pills: Wegovy pill (oral semaglutide 25 mg) and Foundayo (orforglipron, FDA-approved April 1, 2026). They are not interchangeable.
| Wegovy pill | Foundayo | |
|---|---|---|
| Active ingredient | Oral semaglutide 25 mg | Orforglipron (non-peptide GLP-1 receptor partial agonist) |
| Frequency | Once daily | Once daily |
| Timing rules | Take on empty stomach with up to 4 oz water; wait 30 min before eating | None. Take any time, with or without food, with or without water. |
| Avg weight loss in pivotal trial | 13.6% at 64 weeks | 7.4–11.1% at 72 weeks |
| Discontinuation due to side effects | 6.9% (3.4% GI-specific) | 6–10% by dose |
| Notable label side effect | — | Hair loss listed in label (likely related to rapid weight loss, not the drug itself) |
Wegovy pill is the more potent oral option.
It’s the same molecule as Wegovy injection. The label says common adverse reactions with the 25 mg tablet were similar to the injection table — so the pill avoids needles, but it does not prove a gentler stomach experience. If you can’t reliably take a pill on an empty stomach with limited water and wait 30 minutes, you’ll get inconsistent absorption and reduced effect.
Foundayo is the more convenient oral option.
No food rules. No water rules. No ‘did I take it right’ anxiety. It’s a small molecule, not a peptide. The trade-offs: lower average weight loss than Wegovy or Zepbound, slightly higher discontinuation at the top dose, and hair loss listed as a labeled side effect.
A pill is not automatically gentler than a shot.
The fear of injections is real and valid — and oral options solve that. But the GI side effects (nausea, vomiting, constipation, diarrhea) are not proven to disappear when the route changes. Switching from injection to pill does not guarantee a gentler stomach experience.
What If a GLP-1 Already Made Me Sick?
Don't restart on your own. Don't switch drugs on your own.
A bad first experience does not tell you which treatment is right next. Symptoms can have more than one cause, and the next step depends on the medication, interruption length, and your clinical circumstances.
Step 1 — Document what actually happened
- The drug and dose
- The day you took your first injection or pill
- When symptoms started
- What you ate that day
- How much water you drank
- Whether you had a bowel movement
- Other medications you take
- How long the symptoms lasted
- Whether you missed work or normal life
“I felt awful” isn't enough. “I was nauseated for five days starting 36 hours after my second injection, ate two meals total, didn't drink much water, and hadn't had a bowel movement in three days” is enough.
Step 2 — Know when to call right away
- Severe, persistent abdominal pain — especially radiating to the back. Possible pancreatitis.
- Upper-right belly pain with fever or yellowing of the skin / eyes — possible gallbladder disease.
- Vomiting that won’t stop or inability to keep fluids down for 24 hours — dehydration risk.
- A new lump or swelling at the front of your neck, hoarseness, or trouble swallowing — call about thyroid symptoms.
- Sudden vision loss in one eye — the EMA added NAION as a “very rare” labeled side effect for semaglutide medicines in the EU in June 2025. Get evaluated.
- Allergic reaction — hives, swelling, trouble breathing. Emergency.
Step 3 — The data on switching
The most-studied switch is from semaglutide (Wegovy / Ozempic) to tirzepatide (Zepbound / Mounjaro). Some patients tolerate one but not the other — but not everyone. There's no test that predicts who will respond better.
- Do not restart or switch GLP-1 medications on your own. Ask the prescriber what dose and schedule apply to you.
- Restarting and transition instructions differ by medication, interruption length, and clinical circumstances.
- If constipation is contributing to symptoms, ask your clinician what management approach is appropriate for you.
Already failed one GLP-1 and unsure what's next?
Find My GLP-1 Path is a secondary decision aid. It does not diagnose, prescribe, or tell you how to restart a medication.
Find My GLP-1 Path →How to Reduce GLP-1 Side Effects Before They Start
There is no universal side-effect-prevention schedule. Use the medication's labeled escalation plan and ask your prescriber what to do when symptoms affect eating, drinking, daily life, or the next dose.
Pre-start checklist (bring this to your provider visit)
- Confirm the medication’s labeled starting and escalation schedule with your prescriber.
- Ask what to do if a dose is not tolerated before you escalate or take the next dose.
- If constipation is contributing to symptoms, ask your clinician what management approach is appropriate for you.
- Hydration plan. Ask for a daily fluid target that fits your kidney, heart, and medication history.
- If large meals worsen symptoms, ask whether smaller meals would be appropriate for you.
- Ask which foods, drinks, or meal patterns you should avoid if they worsen your symptoms; there is no universal trigger list.
- Keep a symptom log. Day, dose, what you ate, how you felt. Patterns show up fast.
- Save your prescriber’s contact for after-hours questions. Know who to call.
- Know how to contact your prescriber if symptoms are severe, persistent, or affecting hydration.
What not to do
- Don’t push through severe vomiting. That’s not “toughing it out” — that’s dehydration risk.
- Don’t ignore dehydration symptoms or delay seeking care for severe vomiting.
- Don’t dose-escalate early or change the schedule because weight loss feels slow.
- Don’t combine multiple GLP-1s.
- Don’t take anti-nausea medication on your own without checking with your prescriber.
- Don’t assume a higher dose is required; ask the prescriber what target dose is appropriate.
What GLP-1 Side Effects Mean Stop and Call Your Doctor?
Most GLP-1 side effects are GI, mild to moderate, and resolve as your body adapts. A small set is rare but serious. Aware, not afraid — that's the right frame.
| Symptom | Possible concern | Action | Source |
|---|---|---|---|
| Severe persistent abdominal pain, radiating to the back, with nausea/vomiting | Pancreatitis | Stop the drug and seek immediate evaluation | Drug label warnings/precautions |
| Upper-right belly pain, fever, jaundice (yellow skin/eyes) | Gallbladder disease | Seek evaluation; rapid weight loss raises gallstone risk | Drug label warnings/precautions |
| New neck lump, hoarseness, trouble swallowing | Thyroid concerns; MTC/MEN 2 contraindication | Call your doctor | Boxed warning on every GLP-1 label |
| Sudden, painless vision loss in one eye | NAION (very rare) | Seek immediate evaluation | EMA PRAC review for the EU, June 2025 |
| Vomiting that won’t stop or trouble keeping fluids down for 24 hours | Dehydration / acute kidney injury | Stop the drug and seek evaluation | Drug label warnings |
| Hives, swelling, trouble breathing | Allergic reaction | Emergency care | Drug label hypersensitivity contraindication |
| Symptoms of low blood sugar (if on insulin or sulfonylurea) | Hypoglycemia | Call prescriber; dose may need to be reduced | Drug label drug interactions |
Thyroid C-cell tumors. Boxed warning on every GLP-1 label. The warning comes from rodent studies — there is no confirmed human causation. But the FDA contraindicates GLP-1 use if you or a family member have medullary thyroid cancer (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).
Hypoglycemia. Mostly a risk if you take insulin or sulfonylureas (other diabetes drugs that lower blood sugar). GLP-1s alone rarely cause low blood sugar — but combined with those drugs, the risk goes up.
Mental health update. FDA requested removal of suicidal behavior and ideation warning language on January 13, 2026 after its evaluation did not identify an increased risk. The February 2026 U.S. Zepbound label shows that warning as removed; older articles may still mention it.
See our GLP-1 contraindications guide for the complete list →
Are Compounded GLP-1s Gentler Than FDA-Approved GLP-1s?
Short answer: No reliable evidence supports that claim.
Compounded versions are not FDA-approved, and the FDA has not reviewed them for safety, effectiveness, or quality before marketing. Strength, formulation, source/manufacturing controls, and dosing instructions can vary — which makes side-effect outcomes less predictable, not more.
What the FDA actually said
- Fraudulent compounded semaglutide and tirzepatide products flagged
- Fake labels and non-existent pharmacies on labels
- Quality, source, and storage concerns in unverified bulk substance suppliers
- Salt-form and dosing-error concerns
- Tirzepatide shortage resolved December 19, 2024. Semaglutide shortage resolved February 21, 2025.
- April 30, 2026: FDA proposed not including semaglutide, tirzepatide, and liraglutide on the 503B Bulks List after finding no clinical need. The public-comment period was extended through July 30, 2026; this remained a proposal at the August 31 review.
| Claim you'll see elsewhere | Why we won't make it |
|---|---|
| “Same active ingredient as Wegovy / Zepbound / Ozempic” | Compounded is not FDA-reviewed; we won’t equate it with FDA-approved |
| “Generic Wegovy” or “Generic Zepbound” | These drugs do not have FDA-approved generics |
| “Clinically proven like the brand-name drug” | Compounded versions don’t share the brand-name trial evidence base |
| “FDA-approved compounded GLP-1” | A compounded product is, by definition, not FDA-approved |
| “Gentler than FDA-approved” | No data supports this |
For a safety-first reader, FDA-approved is the right answer. The FDA-approved drugs have published, replicable side-effect data — that's what makes the matrix at the top of this page possible. Compounded products don't have that. If your priority is lowest-cost compounded after weighing the trade-offs, see our GLP-1 telehealth provider comparison guide.
Real Reader Voices — Why This Search Matters
Pulled from public Reddit threads (r/GLP1, r/Mounjaro, r/WegovyWeightLoss; accessed May 2026). Not medical evidence.
“the side effects people talk about really scare me”
“Looking for the mildest ones”
“I tried one 0.25 mg shot of semaglutide and was practically unable to function”
“I had no idea that there were differences… I thought ozempic, wegovy, mounjaro etc were all the same”
In the FDA-label trials above, the large majority of participants did not discontinue because of adverse reactions. That 's the reassurance the comments don't give you. Side-effect fear is not a sign you shouldn't do this. It's a sign you're being responsible. The decision-aware reader who titrates slowly, hydrates well, eats smaller meals, treats constipation early, and stays in contact with their prescriber is the one who succeeds.
Where Should You Start for FDA-Approved GLP-1 Access?
Ro is the primary commercial path on this page. Its current membership and medication details were checked ; prices and eligibility can change.
| Fact | Source | Status |
|---|---|---|
| Ro Body membership pricing varies by plan and current provider offer; medication is separate | ro.co/weight-loss/pricing | Provider-stated, checked August 31, 2026 |
| Ro lists Zepbound pen, Wegovy pen, and Ozempic as eligible GLP-1s through insurance | ro.co/weight-loss/pricing | Provider-stated, checked August 31, 2026 |
| Ro lists Wegovy pill, Foundayo, and Zepbound KwikPen as FDA-approved cash-pay options | ro.co/weight-loss/pricing | Provider-stated, checked August 31, 2026 |
| Ro government-plan coordination is limited (FEHB exception) | ro.co | Provider-stated, checked August 31, 2026 |
Primary FDA-approved path
Ro
Why Ro for this page: it connects eligible members with licensed providers, ongoing messaging, and FDA-approved injection or pill options. Eligibility and the available medication depend on clinician review and location.
Pricing: Ro’s membership and medication prices are separate. The amount you pay depends on the current plan, medication, dose, insurance, and location; review Ro’s live pricing before enrolling.
Best fit: readers who want one clinician-led starting path for FDA-approved options, insurance questions, and ongoing support.
Not best fit: readers seeking a specific medication without clinician review or a compounded product.
Review insurance options and see whether you may qualify.
Frequently Asked Questions
- Which GLP-1 has the absolute fewest side effects?
- There is no universal winner. Among FDA-approved weight-loss options, Zepbound 5 mg has a labeled adverse-reaction discontinuation rate of 4.8%, while Wegovy HD 7.2 mg is listed at 5%. In the head-to-head SURMOUNT-5 trial, tirzepatide had lower GI-event discontinuation than semaglutide (2.7% vs 5.6%). These figures come from different kinds of evidence and are not a promise about an individual response.
- Is Zepbound easier to tolerate than Wegovy?
- The SURMOUNT-5 head-to-head trial showed Zepbound produced 20.2% weight loss vs Wegovy’s 13.7%, with GI-event discontinuation of 2.7% vs 5.6% for Wegovy. In that trial, Zepbound users were less likely to quit because of GI side effects. Both still cause GI symptoms.
- Is the Wegovy pill easier on the stomach than the injection?
- The Wegovy label says common adverse reactions with the 25 mg tablet were similar to the injection table. The pill avoids needles, which is the real benefit, but it does not prove a gentler stomach experience. It also has strict timing rules (empty stomach, limited water, wait 30 min before eating) that trip people up.
- How long do GLP-1 side effects last?
- Timing and duration vary by medication, dose, and person; symptoms can occur during dose escalation. In the pivotal trials summarized in the labels, most reported GI events were non-serious and mild to moderate. Ask the prescriber what to do if symptoms persist or worsen.
- Does titrating slowly really make a difference?
- A small 2025 randomized, open-label semaglutide pilot in 104 adults with type 2 diabetes compared a flexible 16-week titration with an 8-week label-based schedule. Nausea was 45.1% versus 64.2% and GI-event withdrawal was 2% versus 19%, but this is supporting evidence, not a universal dosing plan.
- Are compounded GLP-1s gentler than FDA-approved ones?
- No reliable evidence supports that. Compounded versions are not FDA-approved and the FDA has not reviewed them for safety, effectiveness, or quality before marketing. FDA proposed not including semaglutide, tirzepatide, and liraglutide on the 503B Bulks List; the public-comment period was extended through July 30, 2026. As of this August 31 review, that remains a proposal unless FDA has issued a newer final determination.
- Which GLP-1 has the lowest discontinuation rate?
- The labels list adverse-reaction discontinuation rates of 4.8% for Zepbound 5 mg, 6.3–6.7% for other Zepbound doses, 6.8% for Wegovy 2.4 mg, 6.9% for the Wegovy pill, 6–10% for Foundayo by dose, and about 10% for Saxenda. Separate trials are not head-to-head rankings.
- What’s the deal with the suicidal ideation warning I saw?
- FDA requested removal of suicidal behavior and ideation warning language on January 13, 2026 after its evaluation did not identify an increased risk. The February 2026 U.S. Zepbound label shows that warning as removed; check the current label for any medication rather than relying on an older page.
Still not sure? Take the quiz.
The matrix above is the population data. You're a person. Five questions. No signup. You'll get side-effect-aware talking points and a starting path you can take to a clinician.
Find My GLP-1 Path →What We Actually Verified
| Item | Source | Verification date | Status |
|---|---|---|---|
| Zepbound side-effect rates and discontinuation by dose | DailyMed Zepbound USPI | August 31, 2026 | Independently verified from label |
| Wegovy injection 2.4 mg side-effect rates | DailyMed Wegovy USPI | August 31, 2026 | Independently verified from label |
| Wegovy 7.2 mg side-effect rates | DailyMed Wegovy USPI (current 2026 version) | August 31, 2026 | Independently verified from label |
| Wegovy pill (oral semaglutide 25 mg) side-effect language | DailyMed Wegovy USPI | August 31, 2026 | Independently verified from label |
| Foundayo side-effect rates and dosing | Eli Lilly Foundayo USPI (April 2026 FDA approval) | August 31, 2026 | Independently verified from label |
| Saxenda side-effect rates | DailyMed Saxenda USPI | August 31, 2026 | Independently verified from label |
| SURMOUNT-5 head-to-head data | NEJM 2025 publication; ACC journal scan summary | August 31, 2026 | Independently verified from peer-reviewed source |
| Slow titration nausea reduction | 2025 open-label semaglutide titration pilot | August 31, 2026 | Independently verified from peer-reviewed source |
| FDA compounded GLP-1 status and 503B proposal | FDA postmarket safety communications; April 30, 2026 503B bulks list proposal | August 31, 2026 | Independently verified from primary source |
| Suicidal ideation warning removal request | FDA Drug Safety Communication, January 13, 2026 | August 31, 2026 | Independently verified from primary source |
| NAION addition to semaglutide labels | EMA PRAC, June 2025 | August 31, 2026 | Independently verified from primary source |
| Ro pricing, membership, and coverage details | ro.co/weight-loss/pricing | August 31, 2026 | Provider-stated |